MARKET

CASI

CASI

CASI Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.650
0.000
0.00%
After Hours: 1.600 -0.05 -3.03% 17:31 10/19 EDT
OPEN
1.660
PREV CLOSE
1.650
HIGH
1.690
LOW
1.650
VOLUME
64.10K
TURNOVER
--
52 WEEK HIGH
3.670
52 WEEK LOW
1.150
MARKET CAP
204.51M
P/E (TTM)
-4.0660
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ligand: The Small Cap Powering Gilead's Remdesivir
President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week.
Benzinga · 10/05 21:47
CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that research conducted at the New York Blood Center investigating the impact of CID-103 on RBC pretransfusion test
PR Newswire · 10/02 11:00
CASI Pharmaceuticals restructures Juventas Cell Therapy partnership
CASI Pharmaceuticals ([[CASI]] +2.3%) restructured its partnership with Juventas Cell Therapy relating to CNCT19, an investigational CD19 CAR-T Cell therapy.Post restructuring, Juventas can attract fresh capital to assist in upcoming
Seekingalpha · 09/29 13:48
CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced a restructuring of its partnership with Juventas Cell Therapy Ltd. relating to CNCT19, an investigational CD19 CAR-T
PR Newswire · 09/29 11:00
CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the following upcoming
PR Newswire · 09/11 12:00
The CASI Pharmaceuticals (NASDAQ:CASI) Share Price Is Up 53% And Shareholders Are Holding On
Some CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders are probably rather concerned to see the share price fall...
Simply Wall St. · 09/07 13:28
CASI: A Change in Strategy
By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals (NASDAQ:CASI) signaled a shift in its business strategy in March – focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASI’s initial broad-reaching goal to
Zacks Small Cap Research · 08/26 10:31
CASI Pharmaceuticals Q2 EPS $(0.09) Misses $(0.08) Estimate, Sales $2.67M Miss $3.75M Estimate
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 43.75 percent increase over losses of $(0.16) per share
Benzinga · 08/10 11:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CASI. Analyze the recent business situations of CASI Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CASI stock price target is 3.195 with a high estimate of 3.500 and a low estimate of 2.890.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 23.51M
% Owned: 18.97%
Shares Outstanding: 123.94M
TypeInstitutionsShares
Increased
27
1.30M
New
13
-9.03K
Decreased
13
148.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.61%
Pharmaceuticals & Medical Research
-1.74%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Wei-Wu He
President/Chief Financial Officer
Wei Zhang
Other
Alexander Zukiwski
Independent Director
James Huang
Independent Director
Franklin Salisbury
Independent Director
Rajesh Shrotriya
Independent Director
Y. Alexander Wu
Independent Director
Quan Zhou
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CASI Pharmaceuticals Inc stock information, including NASDAQ:CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.